Tricyclic compounds and TXA2 antagonistic compositions thereof

Claim 1

A tricyclic compound of the formula: ##STR144## wherein: X 1 --X 2 is selected from the group consisting of --CH 2 --O-- or ##STR145## (wherein l represents 0, 1, or 2); L is selected from the group consisting of --CH═CH-- or --S--; is a single or double bond; W is selected from the group consisting of --S--, --O--, --NH--, --CH 2 --, --NHCO-- or ═CH--, and the left side of each formula is bound to the tricyclic nucleus; n is 0,1,2, or 3; Z is selected from the group consisting of --NR 1 CO--, --NR 1 SO 2 --, --NR 1 CONH--, --NR 1 CSNH--, --NR 1 NHCONH--, --NR 1 NHCSNH--, --NR 1 COO-- or --NR 1 COS--, wherein R 1 is hydrogen or lower alkyl, and the right side of each formula is bound to Q; Q is selected from the group consisting of optionally substituted, N-substituted or unsubstituted pyrrolyl, (wherein the N-substituent is lower alkyl, phenyl or benzyl), pyridyl, quinolyl or isoquinolyl wherein substitution means 1 to 3 substituents on the aromatic ring, independently selected from lower alkyl, phenyl, benzyl, halogen, triflouromethyl, nitro, OR 2 or SR 2 , (wherein R 2 represents hydrogen, lower alkyl, phenyl or benzyl); one of R A and R B is hydrogen and the other is --Y--M-- wherein Y is selected from the group consisting of a single bond, --CR 3 R 4 --(CH 2 ) m -- and --CR 3 ═CR 4 --(CH 2 ) m )-- and each of R 3 and R 4 are independently hydrogen or lower alkyl and m is 0, 1, 2, 3, or 4, wherein the left side of each formula is bound to the tricyclic nucleus; M is --COOR 5 and R 5 is hydrogen, lower alkyl or --CONR 5a R 5b and each of R 5a and R 5b independently are hydrogen or lower alkyl; each of G A and G B are independently lower alkyl, halogen or OR 6 and R 6 represents hydrogen, lower alkyl, phenyl or benzyl; each of g A and g B are independently 0, 1, 2 or 3; or a pharmaceutically acceptable salt thereof.